Related Experiment Video
Updated: May 18, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Histone deacetylases and cancer
Bruna Barneda-Zahonero1, Maribel Parra
1Cellular Differentiation Group, Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Av. Gran Via s/n km 2.7, 08908 L'Hospitalet, Barcelona, Spain.
Abstract:
Reversible acetylation of histone and non-histone proteins is one of the most abundant post-translational modifications in eukaryotic cells. Protein acetylation and deacetylation are achieved by the antagonistic actions of two families of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs). Aberrant protein acetylation, particularly on histones, has been related to cancer while abnormal expression of HDACs has been found in a broad range of cancer types. Therefore, HDACs have emerged as promising targets in cancer therapeutics, and the development of HDAC inhibitors (HDIs), a rapidly evolving area of clinical research. However, the contributions of specific HDACs to a given cancer type remain incompletely understood. The aim of this review is to summarize the current knowledge concerning the role of HDACs in cancer with special emphasis on what we have learned from the analysis of patient samples.
Insights
Histone deacetylases (HDACs) are crucial in cancer development. This review highlights HDAC roles in various cancers, focusing on insights gained from patient sample analyses to guide targeted therapies.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Reversible protein acetylation is a key post-translational modification in eukaryotes.
- Histone acetyltransferases (HATs) and histone deacetylases (HDACs) regulate acetylation.
- Aberrant acetylation and HDAC expression are linked to cancer development.
Purpose of the Study:
- To review the role of HDACs in cancer.
- To emphasize findings from patient sample analyses.
- To understand specific HDAC contributions to different cancer types.
Main Methods:
- Literature review of existing studies.
- Analysis of patient sample data.
- Synthesis of current knowledge on HDACs in oncology.
Main Results:
- HDACs are implicated in various cancer types.
- Specific HDACs have distinct roles in tumorigenesis.
- Patient sample data provides crucial insights into HDAC functions.
Conclusions:
- HDACs are promising therapeutic targets in cancer.
- Targeted inhibition of specific HDACs may improve cancer treatment.
- Further research on HDACs in patient samples is warranted.
Related Concept Videos
Spreading of Chromatin Modifications
Writers
The writer is an enzyme that can...
Histone Variants at the Centromere
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation

